Loading stock data...

Ambalal Sarabhai Enterprises Limited

BSE: AMBALALSA

BSE
36.16 -0.28 (-0.77%)

Prev Close

36.44

Open Price

36.64

Volume

31,773

Today Low / High

36.05 / 36.64

52 WK Low / High

34.11 / 59.99

Range

34 - 38

The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 36.16, reflecting a change of -0.28 (-0.76839%). The expected target range on the BSE is 34 - 38. The stock is showing a downward trend on the BSE. This could indicate a potential risk for investors who are considering buying at this moment.

11 Jul 36.64 -1.31%
10 Jul 36.11 0.91%
09 Jul 36.73 -1.47%
08 Jul 36.49 -0.33%
07 Jul 36.45 -0.27%
04 Jul 36.22 0.64%
03 Jul 36.83 -1.17%
02 Jul 36.20 0.88%
01 Jul 36.51 -1.48%
30 Jun 37.59 -2.47%
27 Jun 36.39 2.64%
26 Jun 35.89 0.84%
25 Jun 36.26 -2.04%
24 Jun 35.76 -0.08%
23 Jun 35.37 -0.11%
20 Jun 36.10 -1.41%
19 Jun 36.31 -0.58%
18 Jun 36.76 -1.31%
17 Jun 36.91 -0.41%
16 Jun 36.45 1.26%

Ambalal Sarabhai Enterprises Limited Graph

Ambalal Sarabhai Enterprises Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Ambalal Sarabhai Enterprises Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 36.16, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 36.16 36.52 32.87 - 40.17
36.88 29.51 - 44.26
37.24 26.07 - 48.42
Bearish Scenario 36.16 35.80 32.22 - 39.38
35.44 28.35 - 42.52
35.08 24.55 - 45.60

Overview of Ambalal Sarabhai Enterprises Limited

ISIN

INE432A01017

Industry

Medical - Pharmaceuticals

Vol.Avg

77,607

Market Cap

2,771,060,128

Last Dividend

0

Official Website

Visit Website

IPO Date

2000-05-04

DCF Diff

68.79

DCF

-32

Financial Ratios Every Investor Needs

Stock Rating Details for AMBALALSA

Metric Value Recommendation
Overall Rating C Sell
DCF Score 1 Strong Sell
ROE Score 3 Neutral
ROA Score 3 Neutral
Debt-to-Equity (DE) Score 2 Sell
Price-to-Earnings (PE) Score 1 Strong Sell
Price-to-Book (PB) Score 1 Strong Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 196.19 Cr 150.21 Cr 45.98 Cr 0.2344 0.00 Cr 0.00 Cr -2.93 Cr 4.93 Cr 0.64 12.47 Cr 0.0251
2024-03-31 172.94 Cr 102.57 Cr 70.38 Cr 0.4069 0.22 Cr 4.98 Cr 43.68 Cr 5.68 Cr 0.74 17.06 Cr 0.0328
2023-03-31 169.74 Cr 107.43 Cr 62.31 Cr 0.3671 0.11 Cr 4.77 Cr 6.39 Cr 11.45 Cr 1.45 21.33 Cr 0.0674
2022-03-31 195.07 Cr 119.10 Cr 75.97 Cr 0.3894 0.08 Cr 4.67 Cr 21.39 Cr 47.22 Cr 6.16 52.13 Cr 0.2421
2021-03-31 162.77 Cr 103.48 Cr 59.29 Cr 0.3642 0.15 Cr 4.38 Cr 0.56 Cr 29.36 Cr 3.83 22.78 Cr 0.1804

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 11.52 Cr 270.04 Cr 130.07 Cr 139.9729 Cr 50.89 Cr 39.37 Cr 23.63 Cr 62.99 Cr 0.00 Cr 0.00 Cr 62.16 Cr 120.4041 Cr
2024-03-31 10.78 Cr 250.23 Cr 113.09 Cr 137.1328 Cr 46.11 Cr 35.37 Cr 16.18 Cr 63.04 Cr 4.45 Cr 0.00 Cr 34.99 Cr 102.3177 Cr
2023-03-31 10.13 Cr 245.74 Cr 114.82 Cr 130.9231 Cr 41.93 Cr 31.80 Cr 17.43 Cr 64.28 Cr 5.82 Cr 0.00 Cr 38.50 Cr 95.1738 Cr
2022-03-31 12.10 Cr 230.50 Cr 110.65 Cr 119.8665 Cr 26.75 Cr 14.65 Cr 15.14 Cr 45.41 Cr 5.22 Cr -1.88 Cr 36.79 Cr 105.4681 Cr
2021-03-31 14.74 Cr 210.05 Cr 136.16 Cr 73.8981 Cr 27.94 Cr 13.20 Cr 15.97 Cr 33.06 Cr 4.33 Cr -2.55 Cr 28.08 Cr 128.5411 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 -19.0382 Cr 10.6431 Cr 2.5136 Cr -21.7570 Cr 0.0000 Cr 11.5161 Cr -2.7188 Cr 4.9311 Cr 3.4974 Cr 0.0000 Cr -7.4507 Cr
2024-03-31 2.2388 Cr -1.1256 Cr -2.9454 Cr 1.6121 Cr 0.6463 Cr 10.7761 Cr -3.1052 Cr 5.6807 Cr 1.6791 Cr 0.0000 Cr 1.2277 Cr
2023-03-31 5.7245 Cr -16.7818 Cr 9.0854 Cr -14.9438 Cr -1.9719 Cr 10.1298 Cr -20.6683 Cr 14.8252 Cr 14.5198 Cr 0.0000 Cr -2.2819 Cr
2022-03-31 11.4721 Cr 5.0768 Cr -19.1857 Cr -4.2391 Cr -2.6368 Cr 12.1017 Cr -15.7112 Cr 54.1935 Cr -2.0183 Cr 0.0000 Cr 0.8247 Cr
2021-03-31 -2.2989 Cr 10.0898 Cr -5.8401 Cr -4.7582 Cr 1.9508 Cr 14.7385 Cr -2.4593 Cr 32.5407 Cr -2.3562 Cr 0.0000 Cr 0.4731 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-03-31 64.81 Cr 50.08 Cr 14.73 Cr 0.2273 -2.61 Cr -0.27 Cr -0.03 0.04 Cr -0.0041
2024-12-31 45.97 Cr 27.56 Cr 18.41 Cr 0.4005 -1.69 Cr 2.23 Cr 0.29 5.06 Cr 0.0485
2024-09-30 44.70 Cr 23.80 Cr 20.91 Cr 0.4677 1.52 Cr 2.62 Cr 0.34 5.34 Cr 0.0586
2024-06-30 40.70 Cr 31.41 Cr 9.28 Cr 0.2281 10.26 Cr 0.35 Cr 0.05 3.14 Cr 0.0085
2024-03-31 54.35 Cr 38.21 Cr 16.13 Cr 0.2968 5.48 Cr 8.29 Cr 1.18 10.52 Cr 0.1525

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-03-31 11.52 Cr 0.00 Cr 11.52 Cr 44.21 Cr 23.63 Cr 118.48 Cr 62.99 Cr 270.04 Cr 130.07 Cr
2024-12-31 0.00 Cr 0.00 Cr 25.91 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -140.39 Cr
2024-09-30 3.39 Cr 27.02 Cr 30.41 Cr 0.00 Cr 25.54 Cr 128.61 Cr 64.07 Cr 260.46 Cr 120.07 Cr
2024-06-30 0.00 Cr 0.00 Cr 26.72 Cr 0.00 Cr 0.00 Cr 26.72 Cr 0.00 Cr 0.00 Cr -137.14 Cr
2024-03-31 32.90 Cr 27.08 Cr 32.90 Cr 30.45 Cr 16.18 Cr 118.54 Cr 63.04 Cr 250.23 Cr 113.09 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2024-12-31 2.23 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 2.62 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 0.35 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-03-31 8.29 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2023-12-31 1.18 Cr 2.27 Cr 0.00 Cr 0.00 Cr 2.27 Cr 24.62 Cr 22.36 Cr 0.00 Cr 2.27 Cr

Splits History

Date Label Split Ratio
No split history data available.

Similar Stocks: Medical - Pharmaceuticals

Company Name Symbol Price Market Cap Volume
MedPlus Health Services Limited MEDPLUS ₹874.35 ₹104,654,300,261.00 ₹103,212.00

Key Executives

Chief Financial Officer
Mr. Jinal Jaykumar Shah

Gender: male

Year Born:

Whole-Time Director
Ms. Chaula M. Shastri

Gender: female

Year Born: 1959

President of Electronics Division & Chief Operating Officer of Electronics Division
Mr. Mohandas K. Nair

Gender: male

Year Born: 1948

Chairman & Whole Time Director
Mr. Kartikeya Vikram Sarabhai M.A.

Gender: male

Year Born: 1947

MD & Director
Mr. Mohal Kartikeya Sarabhai

Gender: male

Year Born: 1970

Company Secretary & Compliance Officer
Ms. Disha Mahesh Punjani

Gender: female

Year Born:

FAQs about Ambalal Sarabhai Enterprises Limited

Who is the CEO of the company?

The CEO is Kartikeya Vikram Sarabhai.

What is the current market price of the stock?

The current price is ₹36.16.

What is the 52-week price range?

The range is ₹34.11-59.99.

What is the market capitalization of the company?

The market capitalization is ₹277.11 crores.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 54.61.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Ambalal Sarabhai Enterprises Limited (ISIN: INE432A01017) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹277.11 crores and an average daily volume of 77,607 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.

Welcome to the Investing and Trading Information platform: InvesTrack.in

Note: This platform is for educational and informational purposes only. Do not consider anything as financial advice.

QUICK LINKS

Home
About us
Contact us
Privacy Policy
Disclaimer
Sitemap
Investing
Trading
Top Brokers
Tools
Live Analysis

STAY CONNECTED

Follow Us On Social Media
Get Latest Update On Social Media
Facebook Instagram Twitter

General Disclaimer: InvesTrack is an educational platform and not any type of investment advisory platform. Our Blog and videos are based on countless hours of research and experience, which you can use as a guide for your research purposes. None of our content should be considered a piece of investment advice. Earning Disclosure: InvesTrack is a community supported platform. We may earn a commission when you make a purchase through one of our links at no extra cost to you. Note: We are not SEBI Registered Advisors. This website is purely for training and educational purposes. We shall not be responsible for your profit or loss.

© Copyright 2024 - 2025 | InvesTrack